Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for  months ( days) after the last dose of atezolizumab,  months after the last dose of bevacizumab, and  months after the last dose of mFOLFOX; Men with female partners of child-bearing potential must agree to use adequate contraception prior to the study, for the duration of study participation, and for  months after the last dose of bevacizumab and  months after the last dose of mFOLFOX
Subjects must agree to use adequate contraception (i.e. barrier method) for the duration of study participation, and for three months after discontinuing therapy
Patients must agree to use adequate contraception (barrier method for males) for the duration of study participation, and for three months after discontinuing therapy
Female subjects of childbearing potential must agree to use adequate contraception (e.g., hormonal or barrier method of birth control; abstinence) for the duration of study treatment and  months after completion
Women of child bearing age must have pregnancy test at time of enrollment, agree to use of adequate contraception (birth control hormone or barrier method) for the duration of the study and for six months after discontinuation of systemic agents
Sexually active male and female patients should use effective birth control (abstinence; hormonal or barrier method) for the duration of the study and at least  months from last dose.
Females of childbearing potential and males must be willing to abstain from heterosexual activity or must agree to use adequate contraception (hormonal or barrier method) for the duration of study participation and for  weeks after discontinuation of study treatment.
Not pregnant, and if of childbearing potential, agrees to use adequate birth control (hormonal or barrier method of birth control or abstinence) prior to study entry and during the study and agrees not to donate sperm or ova, for the duration of the study and  months post implantation of the investigational device (refer to Section . Permissible and Prohibited Medications/Treatments)
Patients must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry, for the duration of chemoradiation (treatment) and for  months after discontinuing treatment; women of childbearing potential must have a negative serum or urine pregnancy test within  days prior to starting treatment
Pregnant women are excluded from this study; women of child-bearing potential and men must agree to use contraception prior to study entry and for the duration of study participation; acceptable forms of birth control include: birth control pills plus a barrier method, such as a condom or diaphragm, intrauterine devices (IUD) plus a barrier method, implantable or injectable birth control (such as NorplantR or epo-ProveraR) started at least  months before joining the study, plus a barrier method, or double-barrier method, such as a condom when used in combination with a diaphragm; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician
Pregnancy or lactation; patients must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry, for the duration of study participation and for  months after discontinuing therapy
Eligibility criteria specific to the abemaciclib arm:\r\n* Participants must be willing and able to provide written informed consent/assent for the abemaciclib arm of the INSIGhT trial\r\n* Women of child bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from date of initial dose and for  months following the last dose of abemaciclib
Eligibility criteria specific to the neratinib arm:\r\n* Participants must be willing and able to provide written informed consent/assent for the neratinib arm of the INSIGhT trial\r\n* Women of child bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from date of initial dose and for  days following the last dose of neratinib; men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) during intercourse with women of childbearing potential from date of initial dose and for  months following the last dose of neratinib
Pregnant or breast feeding; for all sexually active patients, the use of adequate contraception (hormonal or barrier method of birth control) will be required during therapy, prior to study entry, and for the duration of study participation; non-pregnant status will be determined in all women of childbearing potential
Women of child-bearing potential must use birth control (oral contraceptive, barrier, abstinence or any other acceptable method) for the duration of the study
Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) during treatment
Women of childbearing potential must use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry until  months after the infusion of IMA product
Patients who are pregnant, breastfeeding or plan to become pregnant; sexually active patients and their partners must be willing to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during the study participation, and for four months after the last dose of T-VEC
Is pregnant or breast-feeding, since the effects of NPC-C on the developing human fetus and nursing infants are unknown and potentially harmful, women of child-bearing potential must agree to use adequate contraception (hormonal or double barrier method of birth control or complete abstinence) prior to study entry, for the duration of study participation, and for three months after the last dose of investigational agent.
Males and females of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and for  months after the last dose of study chemotherapy
Patient agrees to use adequate contraception (barrier method of birth control) prior to study entry, during therapy and up to  months after last dose of ipilimumab
Because of the unknown potential risk to a gamete and/or developing embryo from these investigational therapies, patients must agree to use adequate contraception (barrier method for males) for the duration of study participation, and for three months after discontinuing therapy.
Women of childbearing potential and sexually active males must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to enrollment and for the duration of study participation; protections against pregnancy must be continued for at least  months after the last dose of study drug
Females of childbearing potential and males should agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation
For all sexually active patients, the use of adequate contraception (hormonal or barrier method of birth control) will be required prior to study entry and for the duration of study participation; non-pregnant status will be determined in all women of childbearing potential
The effects of dendritic cell vaccines on the developing human fetus are unknown; for this reason men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation
Must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation
Pregnant and breastfeeding women are excluded; as well as women of child-bearing potential who are unwilling or unable to use an acceptable method of birth control (hormonal or barrier method of birth control; abstinence) to avoid pregnancy for the duration of the study
Patient of childbearing potential (defined by the clinical sites' standards) is using adequate birth control measures (e.g., barrier method with spermicide; intrauterine device; implantable or injectable hormonal contraceptives; surgical sterilization) for the duration of the study and will continue to use such precautions for  months after receiving treatment.
Female subjects of childbearing potential and males must agree to use adequate contraception (e.g., hormonal or barrier method of birth control; abstinence) for the duration of study treatment
Pregnancy and breast feeding are exclusion factors; enrolled patients must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, the duration of study participation and  months after the end of the treatment
Participants of child-bearing or child-fathering potential must agree to use adequate contraception (hormonal birth control; intrauterine device; double barrier method; or total abstinence) throughout their participation, including up until  days after last dose of CUDC-
Patients who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection during the study and for  week after the last dose of ranolazine
Willing to use adequate contraception (barrier method, abstinence, subject has had a vasectomy or partner is using effective birth control or is postmenopausal) for the duration of study participation
Female subjects of child-bearing potential must agree to use an adequate form of contraceptive (e.g., hormonal, barrier method or abstinence) prior to study entry and for the duration of the trial.
Fertile subjects must use adequate contraception (abstinence, barrier methods, or birth control pills) prior to study entry and for the duration of study participation
TREATMENT GROUP: Not pregnant and willing to use adequate contraception (barrier method of birth control or abstinence) for the duration of study participation
NORMAL GROUP: Not pregnant and willing to use adequate contraception (barrier method of birth control or abstinence) for the duration of study participation
